A new review highlights the need for personalised and collaborative approaches in managing gestational diabetes, incorporating emerging precision tools and patient involvement to enhance outcomes and experience.
Gestational diabetes remains one of the most common complications of pregnancy, but the condition is far from uniform. The Dove Press review says rates vary widely by region and that women who develop it face higher risks of caesarean delivery, hypertension, premature rupture of membranes and later type 2 diabetes. It also notes that management can be demanding, involving frequent glucose checks, dietary changes and, for some women, medication. That burden, the review argues, makes a stronger case for care that is both more individualised and more collaborative.
A central theme in the review is shared decision-making, which it presents as a practical way to give patients a greater role in choosing how their pregnancy is managed. The paper says women with gestational diabetes often want more say in screening, treatment and delivery planning, yet many describe care as paternalistic or overly focused on laboratory targets. It also points to barriers such as limited consultation time, technical language and low health literacy. In that setting, the authors argue, decision aids and structured conversations can help align treatment with a woman’s values, circumstances and level of risk.
Recent research adds weight to that argument. A systematic review and meta-analysis indexed in PubMed found that precision medicine approaches may improve treatment of gestational diabetes, while also stressing that more evidence is needed before such strategies are widely adopted. Another review in Nature Communications highlighted prognostic risk factors for both mothers and children, reinforcing the case for finer risk stratification rather than a one-size-fits-all model. Together, these studies support the review’s view that gestational diabetes should be managed according to individual risk, not just broad diagnostic categories.
The review also points to emerging precision tools that could reshape care. It discusses genetic markers such as MTNR1B, which have been linked to fasting glucose levels and insulin secretion, and says gut microbiota patterns may also help explain why women respond differently to diet and treatment. At the same time, a clinical update in the medical literature cautions that these findings are promising but not yet ready for routine use in most antenatal clinics. In other words, precision medicine is moving from theory towards practice, but the evidence base is still developing.
That future may also include decision-support systems built on data rather than intuition alone. A Nature Scientific Reports study described an explainable machine learning model designed to predict gestational diabetes using clinical and demographic information, while an Endocrine Society review argued that oral glucose tolerance test patterns may reveal distinct disease subtypes, especially in women with obesity. The shared message across these papers is that gestational diabetes is biologically diverse, and that better prediction, better communication and better patient involvement could improve both outcomes and experience.
For now, the Dove Press review says the strongest case is for blending the two approaches. Precision medicine can help identify risk and guide treatment, while shared decision-making can ensure that women understand their options and help shape the plan. The authors say that combination could make care more effective, more acceptable and more sustainable, although they also acknowledge that pilot programmes and clinical trials are needed before it can be widely adopted.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
